| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
M2-expressing B cells produced more calcium-mobilizing TH cells when pulsed with OVA Peptide (323-339) at 0.01 μM than did M2Y-expressing B cells. In order to determine if B cells expressing M2 can also stimulate more robust individual responses, we measured the MFI of reactive T cells (405/530 ratio) [1].
|
|---|---|
| ln Vivo |
The T and B cell epitope of OVA, represented by OVA Peptide (323–339), is crucial for the onset and progression of acute hypersensitivity reactions in BALB/c mice. Sensitization to native OVA via the same mechanism was found to be just as effective in inducing serum anti-OVA IgE antibody responses as nebulizing OVA Peptide (323-339) for 20 minutes every day for ten days. Most IgE anti-OVA responses are directed against OVA Peptide after exposure to native OVA (323-339). Comparable lung inflammation is produced by OVA and OVA Peptide (323–339), according to hematoxylin/eosin and major basic protein immunohistochemistry staining. Interestingly, when OVA mice were compared to saline controls, there was a substantial increase in serum total IgE and OVA-specific IgE. Similar to OVA mice, OVA Peptide (323-339) animals exhibited reduced IFN-γ, IL-4, and greater blood levels of OVA-specific IgE. Splenocytes from OVA and OVA Peptide (323–339) mice exhibited a proliferative response when exposed to OVA, but only splenocytes from OVA Peptide (323–339) animals showed a similar proliferative response when exposed to OVA Peptide (323–339). These mice were both challenged and sensitized. While both OVA and OVA Peptide (323–339) elicit Th2-like responses in mouse models, OVA Peptide (323–339) has a much lower immunogenic potency when it comes to stimulating the spleenocytes of mice that have been challenged and sensitized to OVA. [2].
|
| References |
|
| Molecular Formula |
C74H120N26O25
|
|---|---|
| Molecular Weight |
1773.90
|
| Exact Mass |
1772.89
|
| CAS # |
92915-79-2
|
| PubChem CID |
56832351
|
| Appearance |
White to off-white solid powder
|
| LogP |
-9.9
|
| Hydrogen Bond Donor Count |
28
|
| Hydrogen Bond Acceptor Count |
29
|
| Rotatable Bond Count |
59
|
| Heavy Atom Count |
125
|
| Complexity |
3800
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)N
|
| InChi Key |
GSSMIHQEWAQUPM-AOLPDKKJSA-N
|
| InChi Code |
InChI=1S/C74H120N26O25/c1-12-33(5)55(77)70(121)98-49(29-101)69(120)94-42(16-19-50(75)102)63(114)88-39(11)62(113)99-56(32(3)4)71(122)96-47(24-41-27-81-31-85-41)67(118)89-36(8)59(110)86-37(9)61(112)95-46(23-40-26-80-30-84-40)66(117)90-38(10)60(111)92-44(18-21-54(107)108)65(116)100-57(34(6)13-2)72(123)97-48(25-51(76)103)68(119)93-43(17-20-53(105)106)64(115)87-35(7)58(109)83-28-52(104)91-45(73(124)125)15-14-22-82-74(78)79/h26-27,30-39,42-49,55-57,101H,12-25,28-29,77H2,1-11H3,(H2,75,102)(H2,76,103)(H,80,84)(H,81,85)(H,83,109)(H,86,110)(H,87,115)(H,88,114)(H,89,118)(H,90,117)(H,91,104)(H,92,111)(H,93,119)(H,94,120)(H,95,112)(H,96,122)(H,97,123)(H,98,121)(H,99,113)(H,100,116)(H,105,106)(H,107,108)(H,124,125)(H4,78,79,82)/t33-,34-,35-,36-,37-,38-,39-,42-,43-,44-,45-,46-,47-,48-,49-,55-,56-,57-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 50 mg/mL (28.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (28.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5637 mL | 2.8186 mL | 5.6373 mL | |
| 5 mM | 0.1127 mL | 0.5637 mL | 1.1275 mL | |
| 10 mM | 0.0564 mL | 0.2819 mL | 0.5637 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
